Type 2 diabetes weight loss medication and treatment options

For type 2 diabetes weight loss medication, the ADA's 2026 Standards prefer a GLP-1 or dual GIP/GLP-1 drug: Zepbound, Wegovy or Foundayo for weight, Mounjaro or Ozempic for blood sugar. People with diabetes lose less on these than people without it, roughly 9.6% to 14.7% on average in trials. Metformin, SGLT2 inhibitors and insulin remain part of treatment.

What it is

Type 2 diabetes is a long-term condition in which the body does not respond well to insulin and, over time, does not make enough of it, so blood sugar runs high.

The ADA's 2026 Standards diagnose it with any of these, confirmed by a repeat test unless the result is unmistakable (ADA Standards of Care 2026, Section 2):

  • A1C of 6.5% or higher
  • Fasting plasma glucose of 126 mg/dL or higher
  • 2-hour glucose of 200 mg/dL or higher on a 75 g oral glucose tolerance test
  • Random glucose of 200 mg/dL or higher with classic symptoms such as thirst and frequent urination

The ADA now advises testing all adults from age 35. Our A1C to average glucose tool converts an A1C result into everyday numbers.

Why it matters

About 38.4 million Americans have diabetes, 11.6% of the population, and 8.7 million of them do not know it (CDC National Diabetes Statistics Report). Most have type 2.

Weight is central to it. The ADA says that in people with type 2 diabetes and overweight or obesity, weight management should be a primary goal alongside glucose control. Losing 5% to 7% improves blood sugar, and sustained loss above 10% can modify the disease and sometimes put it into remission (ADA Standards of Care 2026, Section 8). In the DiRECT trial, 46% of people on a structured weight program were in remission at one year (Lancet, 2018).

Treatment options

Treatment options, the evidence for each, and who each suits
OptionWhat it isEvidenceBest for
Nutrition, activity and weight managementStructured eating, regular activity and diabetes self-management education. Intensive programs can include short-term total diet replacement.DiRECT (Lancet 2018): 46% of the intervention group were in remission at 12 months; remission reached 86% among those who lost 15 kg or more.Everyone with type 2 diabetes, and especially those diagnosed recently, where remission is most often reported.
MetforminA long-standing, low-cost oral medicine that reduces glucose made by the liver. Weight loss with it is small, under 3.2% in a 2021 review.In the Diabetes Prevention Program, metformin cut progression from prediabetes to diabetes by 31% versus placebo (NEJM 2002).Many people as a starting medicine, used alone or combined with the options below.
GLP-1 receptor agonists (semaglutide, liraglutide)Weekly or daily medicines that raise insulin when glucose is high, slow digestion and reduce appetite. Ozempic and Rybelsus treat diabetes; Wegovy and Saxenda treat weight.SUSTAIN 6: Ozempic cut major cardiovascular events (hazard ratio 0.74). STEP 2: Wegovy lowered weight 9.6% vs 3.4% and A1C 1.6 vs 0.4 points (labels).People with diabetes plus heart disease, kidney disease or a weight goal.
Dual GIP/GLP-1 agonist (tirzepatide)Sold as Mounjaro for diabetes and Zepbound for weight; the same molecule from Eli Lilly, given weekly.SURPASS-2: A1C fell 2.3 points on 15 mg vs 1.9 on semaglutide 1 mg. SURMOUNT-2: weight fell 14.7% on 15 mg vs 3.2% on placebo (labels).People who need large reductions in both A1C and weight.
SGLT2 inhibitorsDaily pills such as empagliflozin and dapagliflozin that make the kidneys pass extra glucose into the urine.The ADA 2026 Standards recommend a GLP-1 drug and/or an SGLT2 inhibitor for adults with type 2 diabetes and established or high risk of heart disease.People with heart failure, kidney disease or high cardiovascular risk.
Insulin and other glucose-lowering drugsBasal or mealtime insulin, sulfonylureas, DPP-4 inhibitors and others, chosen by A1C, cost and risk of low blood sugar.Covered in ADA Standards of Care 2026, Section 9. Insulin and sulfonylureas raise hypoglycemia risk when combined with GLP-1 drugs (Ozempic label).People whose A1C stays above target despite other medicines.

Approved medications

Medications approved for this condition and the trial behind each
MedicationApproved forKey trial
Zepbound (tirzepatide)Weight management in adults with BMI ≥30, or ≥27 with a condition such as type 2 diabetesSURMOUNT-2 (adults with type 2 diabetes): −12.8% (10 mg) and −14.7% (15 mg) vs −3.2% placebo at 72 weeks
Wegovy (semaglutide 2.4 mg and 7.2 mg)Weight management in adults with obesity, or overweight with a related condition, including type 2 diabetesSTEP 2: −9.6% vs −3.4% at 68 weeks. Label Study 9 (7.2 mg, diabetes): −13.2% vs −3.8% at 72 weeks
Foundayo (orforglipron) tabletWeight management in adults with obesity, or overweight with a related condition. Not approved to treat diabetes itselfATTAIN-2 (adults with type 2 diabetes): −9.6% (17.2 mg) vs −2.5% placebo at 72 weeks
Mounjaro (tirzepatide)Blood sugar control in type 2 diabetes (adults and ages 10+); cutting major CV events in adults with diabetes at high riskSURPASS-2: A1C −2.3 and weight −11.2 kg (15 mg) vs −1.9 and −5.7 kg (semaglutide 1 mg) at 40 weeks
Ozempic (semaglutide)Blood sugar control in adult type 2 diabetes; cutting CV events with heart disease; slowing kidney decline with CKDSUSTAIN 6: MACE hazard ratio 0.74. FLOW: kidney and CV death composite hazard ratio 0.76
Saxenda (liraglutide 3 mg)Weight management in adults and ages 12+, including adults with type 2 diabetesSaxenda label Study 2 (type 2 diabetes): −5.4% vs −1.7% at 56 weeks

Where GLP-1 medications fit

GLP-1 and dual GIP/GLP-1 drugs are the ADA's preferred obesity medicines for people who also have type 2 diabetes, because they lower weight and glucose together (ADA Standards of Care 2026, Section 8).

Two things are worth knowing before you start:

  • Expect less weight loss than headlines suggest. Tirzepatide 15 mg averaged 20.9% loss in people without diabetes (SURMOUNT-1) but 14.7% in people with it (SURMOUNT-2). Semaglutide 2.4 mg showed the same gap: 14.9% versus 9.6% (STEP 1 and STEP 2).
  • The brand matters for coverage, not chemistry. Mounjaro and Zepbound are both tirzepatide; Ozempic and Wegovy are both semaglutide. The diabetes brand and the weight brand carry different labels, doses and insurance rules. Our semaglutide vs tirzepatide for diabetes comparison covers the trade-offs.

If you take insulin or a sulfonylurea, ask your prescriber: "Should my other diabetes doses change when I start this?"

When to see a doctor in person

See your own diabetes clinician in person for routine A1C, kidney and eye checks, and before any change to insulin or other diabetes medicines. The Zepbound label warns that rapid glucose improvement can temporarily worsen diabetic retinopathy, so people with it need eye monitoring. Get urgent care for blood sugar readings repeatedly above 300 mg/dL with vomiting, confusion or fruity-smelling breath, or for low blood sugar that does not come up after treatment. Wounds on the feet that are not healing also need an in-person exam.

How Temi helps

Temi does not manage diabetes. What it can do is renew a non-controlled medicine you already take, such as metformin: a physician reviews the request and sends it to the pharmacy you choose, for $15 per refill (usetemi.com/prescription/refills, checked 5 Oct 2026). Temi's GLP-1 program is for weight management, and its compounded semaglutide and tirzepatide are not FDA-approved. Keep A1C targets, insulin and diabetes dose changes with your own clinician.

Frequently asked questions

What is the best weight loss medication for type 2 diabetes?

The ADA's 2026 Standards name a GLP-1 receptor agonist or a dual GIP/GLP-1 agonist as the preferred obesity medicine for people with type 2 diabetes. In head-to-head trial data, tirzepatide produced larger average A1C and weight reductions than semaglutide 1 mg (SURPASS-2, Mounjaro label). The best fit still depends on heart and kidney history, side effects and coverage, which your prescriber weighs.

Can you take Zepbound or Wegovy if you have type 2 diabetes?

Yes. Both labels cover weight management in adults with overweight and at least one weight-related condition, and type 2 diabetes counts. Zepbound was tested in people with diabetes in SURMOUNT-2 and Wegovy in STEP 2. They should not be combined with Mounjaro, Ozempic or any other GLP-1 drug, so a prescriber would usually choose one product rather than adding a second.

Can type 2 diabetes go into remission with weight loss?

It can for some people. The ADA notes that sustained weight loss above 10% may modify the disease and lead to remission (ADA Standards of Care 2026, Section 8). In the DiRECT trial, 46% of people on a structured weight program were in remission at 12 months. Remission means normal glucose without diabetes medicines; it needs ongoing monitoring because diabetes can return if weight comes back.

Is Ozempic approved for weight loss in type 2 diabetes?

No. Ozempic is approved to improve blood sugar in adults with type 2 diabetes and to lower cardiovascular and kidney risk in specific groups (Ozempic label). Weight loss is a known effect, but the weight-management indication belongs to Wegovy, which contains the same molecule at different doses. Our Metformin vs Ozempic page compares the two common diabetes options.

Does metformin help you lose weight?

Only modestly. A 2021 review in Pharmacological Research grouped metformin with drugs that produce less than 3.2% weight loss, far less than GLP-1 drugs. Its main job is lowering glucose made by the liver. In the Diabetes Prevention Program, it cut the chance of prediabetes progressing to diabetes by 31%, while the intensive lifestyle program cut it by 58% (NEJM 2002). It is often kept alongside a GLP-1 drug.

Is Foundayo approved for type 2 diabetes?

Not for blood sugar control. Foundayo (orforglipron) was approved on 1 April 2026 for chronic weight management only. Its label includes ATTAIN-2, a trial in adults with type 2 diabetes, where the 17.2 mg dose averaged 9.6% weight loss against 2.5% for placebo at 72 weeks. People with diabetes can use it for weight under that label if a prescriber agrees.

Sources

  1. 2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes—2026 (ADA) (checked October 5, 2026)
  2. 8. Obesity and Weight Management for the Prevention and Treatment of Diabetes: Standards of Care in Diabetes—2026 (ADA) (checked October 5, 2026)
  3. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2026 (ADA) (checked October 5, 2026)
  4. CDC National Diabetes Statistics Report (checked October 5, 2026)
  5. Zepbound (tirzepatide) prescribing information, Eli Lilly (checked October 5, 2026)
  6. Mounjaro (tirzepatide) prescribing information, Eli Lilly (checked October 5, 2026)
  7. Wegovy (semaglutide) injection and tablets prescribing information, Novo Nordisk (checked October 5, 2026)
  8. Ozempic (semaglutide) prescribing information, Novo Nordisk (checked October 5, 2026)
  9. Foundayo (orforglipron) prescribing information, Eli Lilly (checked October 5, 2026)
  10. Saxenda (liraglutide) prescribing information, Novo Nordisk (checked October 5, 2026)
  11. Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin (Diabetes Prevention Program, NEJM 2002) (checked October 5, 2026)
  12. Anti-diabetic drugs and weight loss in patients with type 2 diabetes (Pharmacological Research, 2021) (checked October 5, 2026)
  13. Primary care-led weight management for remission of type 2 diabetes (DiRECT): an open-label, cluster-randomised trial (Lancet 2018) (checked October 5, 2026)
  14. Temi: prescription refills ($15 per refill) (checked October 5, 2026)

Compounded semaglutide and compounded tirzepatide are not FDA-approved generics of the brand-name products. A licensed 503A compounding pharmacy prepares each one for a single prescription.

Get started

Start online, and a licensed physician reviews your request

A short online questionnaire is the first step. No appointments and no insurance needed.

A licensed physician reviews every request. Nothing on this page is a prescription.

The revolution will be emailed.

Once a week, roughly.

We're taking the fight to a corrupt and broken health insurance system. Join up.

Get Temi's newsletter by email. Unsubscribe anytime. Privacy policy